Recent Updates
Recently added Catalysts

Ivonescimab combined with Cadonilimab

Phase 2

Renal Cell Carcinoma, Clear Cell | Monoclonal antibody | Oncology |Summit Therapeutics Inc.|Trials Updated: Oct 16, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment100

FDA Designations

No designations recorded

Ivonescimab combined with Cadonilimab clinical trials

Ivonescimab combined with Cadonilimab · 1 trial · 1 indication

Phase 2 1
NCT07877194A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal CancerRenal Cell Carcinoma, Clear Cell
NOT YET_RECRUITING100 Analytics
PHASE2NOT YET_RECRUITING
A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
Renal Cell Carcinoma, Clear Cell
NCT07877194100
Unlock trial analytics

Study Endpoints

Primary Endpoints

Objective Response Rate (ORR)
From randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.

ORR per RECIST v1.1 by investigator

Adverse Events (AEs)
At the time of initiation of the first dose through 90 days after the last dose of study treatment.

Adverse events (AEs) as characterized by type, incidence, severity, seriousness, and relationship to study treatment

Secondary Endpoints

Disease Control Rate (DCR)
From randomization to first occurrence of disease progression, death or study completion, whichever came first, assessed up to 3 years.
Duration of Response (DoR)
From time of first recorded response randomization to progressive disease, or death or study completion, whichever came first, assessed up to 3 years.
Progression Free Survival (PFS)
From randomization to progressive disease or death, whichever came first, assessed up to 3 years.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Ivo 1 + CadoEXPERIMENTALIvonescimab (dose level 1) + Cadonilimab
Ivo 2 + CadoEXPERIMENTALIvonescimab (dose level 2) + Cadonilimab
Ivo + IpiEXPERIMENTALIvonescimab + Ipilimumab
IvoEXPERIMENTALIvonescimab
Nivo + IpiACTIVE_COMPARATORNivolumab + Ipilimumab

Interventions

NameTypeDescription
Ivonescimab (dose level 1) combined with CadonilimabDRUGSubjects will receive Ivonescimab (dose level 1) combined with Cadonilimab via intravenous infusion (IV) up to 2 years.
Ivonescimab (dose level 2) combined with CadonilimabDRUGIvonescimab (dose level 2) combined with Cadonilimab via intravenous infusion (IV) up to 2 years.
Ivonescimab combined with IpilimumabDRUGIvonescimab combined with Ipilimumab via intravenous infusion (IV) up to 4 cycles. Afterward, Ivonescimab for maintenance treatment up to 2 years total.
IvonescimabDRUGIvonescimab monotherapy via intravenous infusion (IV) up to 2 years.
Nivolumab combined with IpilimumabDRUGNivolumab combined with Ipilimumab via intravenous infusion (IV) up to 4 cycles. Afterward, Nivolumab will be used for maintenance treatment up to 2 years total.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: 1. Able to understand and voluntarily sign a written informed consent form, which must be signed prior to the performance of the designated study procedures required by the study. 2. Age ≥ 18 years both male and female. 3. Karnofsky Performance Status Score (KPS) ≥ 70%. 4. Expec...

Countries:United StatesChina
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 16, 2026NCT07877194NEW_TRIAL: changed
LOWOct 16, 2026NCT07877194NEW_TRIAL: changed

Explore more on BiopharmaWatch

Summit Therapeutics Inc. (SMMT)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ICompanies A to ZEvery biotech and pharma company we track